SPY334.57+0.24 0.07%
DIA274.62+0.72 0.26%
IXIC11,010.98-97.09 -0.87%

UPDATE: H.C. Wainwright Maintains Neutral On Nektar Therapeutics, Raises Target To $32 As Firm Notes 'Upward Bias Exiting SITC'; 'Durability in frontline melanoma is reassuring, but we remain wary'

Do you like seeing these details as to why an analyst recommended a stock? What could we do to make this product better? Let us know by emailing newsdesk@benzinga.com

Benzinga · -